GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• GoodRx Holdings, Inc. has received a consensus rating of "Moderate Buy" from eleven analysts, with an average target price of $6.55 over the next year.
• The company's stock is currently trading at $4.53, down by 5.4%, with a 52-week low of $3.67 and a high of $8.94.
• GoodRx recently reported quarterly earnings of $0.09 EPS, exceeding expectations, and showed a revenue increase of 2.6% year-over-year, totaling $202.97 million.

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $6.5455.

A number of research analysts have commented on GDRX shares. Truist Financial reduced their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group reduced their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. UBS Group reduced their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Finally, Wells Fargo & Company reduced their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th.

GoodRx Trading Down 21.8%

GoodRx stock traded down $0.95 during midday trading on Monday, reaching $3.40. The stock had a trading volume of 5,922,583 shares, compared to its average volume of 1,454,633. GoodRx has a twelve month low of $3.31 and a twelve month high of $8.80. The stock has a market capitalization of $1.21 billion, a PE ratio of 42.44, a price-to-earnings-growth ratio of 1.95 and a beta of 1.24. The company has a debt-to-equity ratio of 0.74, a quick ratio of 5.23 and a current ratio of 5.23. The stock's 50-day simple moving average is $4.62 and its 200 day simple moving average is $4.57.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). GoodRx had a net margin of 3.57% and a return on equity of 7.85%. The firm had revenue of $203.07 million during the quarter, compared to analyst estimates of $205.72 million. During the same quarter in the previous year, the business posted $0.08 EPS. GoodRx's revenue was up 1.2% compared to the same quarter last year. Analysts expect that GoodRx will post 0.13 EPS for the current year.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.53% of the company's stock.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the company. National Bank of Canada FI increased its holdings in GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after buying an additional 2,151 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in GoodRx in the first quarter valued at about $44,000. Jump Financial LLC bought a new stake in GoodRx in the first quarter valued at about $49,000. Deerfield Management Company L.P. Series C bought a new stake in GoodRx in the fourth quarter valued at about $56,000. Finally, Vontobel Holding Ltd. bought a new stake in GoodRx in the second quarter valued at about $58,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.